KCNN4 and glioma: In murine models of glioma, pharmacological inhibition of KCa3.1 has been shown to reduce tumor burden by promoting a phenotypic shift in TAMs from a pro-tumorigenic M2 to an anti-tumorigenic M1 phenotype [60,61].